Tag: Gip agonists

Despite both being injectable medications prescribed for Type 2 diabetes, Bydureon and Mounjaro are not the same and belong to different generations of incretin-based therapies. A key distinction lies in their active ingredients and mechanisms of action, with Mounjaro offering a dual-targeting approach not present in Bydureon.

In 2022, Mounjaro (tirzepatide) received FDA approval, introducing the first-of-its-kind dual GIP and GLP-1 receptor agonist to the market. Understanding **what drugs are in the same class as Mounjaro** is important for patients and providers exploring treatment options for type 2 diabetes and chronic weight management.

A 2024 study published in *JAMA Internal Medicine* found that individuals taking Mounjaro experienced significantly greater weight loss over one year compared to those taking Ozempic in real-world conditions. This and other clinical findings have fueled the debate: **is Mounjaro better than Ozempic** for managing metabolic conditions and weight?

Clinical trial data published in *The New England Journal of Medicine* showed that Zepbound led to a significantly greater average weight loss than Wegovy in a head-to-head study. Determining what is more effective, Wegovy or Zepbound, however, depends on individual patient factors and therapeutic goals.